<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01182649</url>
  </required_header>
  <id_info>
    <org_study_id>AOM_DES02</org_study_id>
    <nct_id>NCT01182649</nct_id>
  </id_info>
  <brief_title>Everolimus Stent in Patients With Coronary Artery Disease (CAD)</brief_title>
  <acronym>RACES</acronym>
  <official_title>Randomized Comparison of Everolimus Eluting Stents and Sirolimus Eluting Stent in Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>San Giuseppe Moscati Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>San Giuseppe Moscati Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is to compare the everolimus eluting stent and sirolimus eluting stent in
      all comers PCI eligible patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compared with the currently available first-generation drug-eluting stents (DES),
      second-generation DES have been designed with the goal of improving safety and efficacy.
      Everolimus, a sirolimus analogue, is released from a open cell, thin-strut, cobalt-chromium
      frame. A significant reduction in cardiac events was noted in patients with the
      everolimus-eluting stent compared with those who had a paclitaxel-eluting stent. Sirolimus
      eluting stent was the first available drug eluting stent and is the most tested. Therefore
      the investigators compared the safety and efficacy of the everolimus-eluting and sirolimus
      eluting stents in unselected patients in real world practice.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target Vessel Revascularization</measure>
    <time_frame>2 year</time_frame>
    <description>Incidence of clinically driven target vessel revascularization at 2 year follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiac death</measure>
    <time_frame>2 year</time_frame>
    <description>incidence of death for cardiac causes at 2 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non fatal myocardial infarction</measure>
    <time_frame>2 year</time_frame>
    <description>incidence of non fatal Q or non Q wave reinfarction at 2 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis</measure>
    <time_frame>2 year</time_frame>
    <description>incidence of definite, probable or possible stent thrombosis at 2 year</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>EES Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who received an everolimus eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SES Gruop</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who received a sirolimus eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>coronary stent</intervention_name>
    <description>coronary angioplasty with stent implantation</description>
    <arm_group_label>EES Group</arm_group_label>
    <other_name>XIENCE V drug eluting stent; Abbot Vascular USA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>stent</intervention_name>
    <description>coronary angioplasty with stent implantation</description>
    <arm_group_label>SES Gruop</arm_group_label>
    <other_name>CYPHER drug eluting stent; Johnson &amp; Johnson USA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with coronary artery disease eligible for percutaneous coronary
             intervention (PCI)

        Exclusion Criteria:

          -  Contraindication to dual antiplatelet therapy for 12 months

          -  Known allergy to sirolimus or everolimus

          -  Major surgical procedure planned within 1 month

          -  History, symptoms, or findings suggestive of aortic dissection.

          -  Participation in other trials

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>EMILIO DI LORENZO, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DIVISION OF CARDIOLOGY AORN MOSCATI AVELLINO ITALY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Cardiology Aorn Moscati</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ; SPIRIT IV Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010 May 6;362(18):1663-74. doi: 10.1056/NEJMoa0910496.</citation>
    <PMID>20445180</PMID>
  </reference>
  <reference>
    <citation>Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010 Jan 16;375(9710):201-9. doi: 10.1016/S0140-6736(09)62127-9. Epub 2010 Jan 7.</citation>
    <PMID>20060578</PMID>
  </reference>
  <reference>
    <citation>Caixeta A, Leon MB, Lansky AJ, Nikolsky E, Aoki J, Moses JW, Schofer J, Morice MC, Schampaert E, Kirtane AJ, Popma JJ, Parise H, Fahy M, Mehran R. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. J Am Coll Cardiol. 2009 Sep 1;54(10):894-902. doi: 10.1016/j.jacc.2009.04.077.</citation>
    <PMID>19712798</PMID>
  </reference>
  <reference>
    <citation>Di Lorenzo E, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G, De Luca G. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. Am Heart J. 2009 Oct;158(4):e43-50. doi: 10.1016/j.ahj.2009.03.016.</citation>
    <PMID>19781402</PMID>
  </reference>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2010</study_first_submitted>
  <study_first_submitted_qc>August 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2010</study_first_posted>
  <last_update_submitted>August 16, 2010</last_update_submitted>
  <last_update_submitted_qc>August 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>EMILIO DI LORENZO MD PhD</name_title>
    <organization>DIVISION OF CARDIOLOGY AO MOSCATI</organization>
  </responsible_party>
  <keyword>Drug Eluting Stents</keyword>
  <keyword>Everolimus Eluting Stent</keyword>
  <keyword>Coronary Angioplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

